Effect of ACE inhibitors and angiotensin receptor blockers on in-hospital mortality and length of stay in hospitalized COVID-19 patients

•ACEi/ARB need not be discontinued in hospitalized COVID-19 patients•ACEi/ARB use need not be restricted due to COVID-19 pandemic•ACEi/ARB benefits for cardiovascular indications outweigh harm in COVID-19 patients.

Saved in:

Bibliographic Details
Published in	Vascular pharmacology Vol. 141; p. 106902
Main Authors	LaClair, Heather J., Khosrodad, Nadia, Sule, Anupam A., Koehler, Tracy, Krishnamoorthy, Geetha
Format	Journal Article
Language	English
Published	United States Elsevier Inc 01.12.2021 Elsevier Science Ltd
Subjects	Angiotensin receptor antagonists Angiotensin Receptor Antagonists - adverse effects Angiotensin-converting enzyme inhibitors Angiotensin-Converting Enzyme Inhibitors - adverse effects Cardiovascular COVID-19 Hospital Mortality Humans Hypertension Length of Stay SARS-CoV-2 COVID-19 Angiotensin-converting enzyme inhibitors Angiotensin receptor antagonists Hospital mortality Length of stay
Online Access	Get full text
ISSN	1537-1891 1879-3649 1879-3649
DOI	10.1016/j.vph.2021.106902

Cover

More Information
Summary:	•ACEi/ARB need not be discontinued in hospitalized COVID-19 patients•ACEi/ARB use need not be restricted due to COVID-19 pandemic•ACEi/ARB benefits for cardiovascular indications outweigh harm in COVID-19 patients.
Bibliography:	SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Correspondence-1 ObjectType-Commentary-2 content type line 23
ISSN:	1537-1891 1879-3649 1879-3649
DOI:	10.1016/j.vph.2021.106902